Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03094416 · ClinicalTrials.gov registry record · Phase 4

Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors

A Phase 4 study, sponsored by IBSA Institut Biochimique.

Completed
Registry status
Phase 4
Development phase
66
Enrollment target

NCT03094416 is a Phase 4 study that has completed, run by IBSA Institut Biochimique. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03094416, a Phase 4 study, has completed, sponsored by IBSA Institut Biochimique.

COMPLETED
Registry status
Phase 4
Development phase
66 participants
Enrollment target

Study Summary

This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating changes in serum levels of Thyroid Stimulating Hormone (TSH) upon switch to Tirosint with respect to baseline.

Interventions

  • DRUG levothyroxine sodium capsule
  • DRUG Proton pump inhibitor (PPI)
  • DRUG Levothyroxine Sodium (LT4) Tablets

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2018-07-30
Est. Completion 2020-06-15
Phase Phase 4

Sponsor

IBSA Institut Biochimique

8 total trials

What the Registry Record Tells You About NCT03094416

The ClinicalTrials.gov registry entry for NCT03094416 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IBSA Institut Biochimique, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which levothyroxine sodium capsule is the first listed.

NCT03094416 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03094416 about?

NCT03094416 is a clinical study titled "Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors". This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating changes in serum levels of Thyroid Stimulating Hormone (TSH) upon switch to Tirosint with respect to baseline.

What is the current status of trial NCT03094416?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2018-07-30. Estimated completion is 2020-06-15.

What interventions are being tested in trial NCT03094416?

The interventions under investigation include: levothyroxine sodium capsule (DRUG), Proton pump inhibitor (PPI) (DRUG), Levothyroxine Sodium (LT4) Tablets (DRUG).

Who is sponsoring clinical trial NCT03094416?

This trial is sponsored by IBSA Institut Biochimique, which has 8 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.